← All Leap Therapeutics, INC filings

Leap Therapeutics, INC 8-K filings

LPTX
Leap Therapeutics, INC
8-K: Leap Therapeutics Announces Positive Clinical Trial Results and Year-End Financials
Leap Therapeutics reported promising clinical data for its DKN-01 drug in cancer trials and its year-end 2023 financial results.
LPTX
Leap Therapeutics, INC
8-K: Leap Therapeutics Provides Corporate Update and Clinical Trial Progress
Leap Therapeutics has released an updated corporate presentation highlighting progress in its clinical programs and financial runway.
LPTX
Leap Therapeutics, INC
8-K: Leap Therapeutics Announces Promising Clinical Data for DKN-01 in Colorectal Cancer
Leap Therapeutics reports positive results from its DeFianCe study, showing DKN-01 in combination with standard therapy demonstrates encouraging efficacy in second-line colorectal cancer patients, particularly those with left-sided tumors.